CA2385817C - Substituted pyridines and pyridazines with angiogenesis inhibiting activity - Google Patents

Substituted pyridines and pyridazines with angiogenesis inhibiting activity Download PDF

Info

Publication number
CA2385817C
CA2385817C CA2385817A CA2385817A CA2385817C CA 2385817 C CA2385817 C CA 2385817C CA 2385817 A CA2385817 A CA 2385817A CA 2385817 A CA2385817 A CA 2385817A CA 2385817 C CA2385817 C CA 2385817C
Authority
CA
Canada
Prior art keywords
cndot
substituted
alkyl
methyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2385817A
Other languages
English (en)
French (fr)
Other versions
CA2385817A1 (en
Inventor
Jacques P. Dumas
Teddy Kite Joe
Harold C. E. Kluender
Wendy Lee
Dhanapalan Nagarathnam
Robert N. Sibley
Ning Su
Stephen James Boyer
Julie A. Dixon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of CA2385817A1 publication Critical patent/CA2385817A1/en
Application granted granted Critical
Publication of CA2385817C publication Critical patent/CA2385817C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
CA2385817A 1999-09-28 2000-09-26 Substituted pyridines and pyridazines with angiogenesis inhibiting activity Expired - Lifetime CA2385817C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40760099A 1999-09-28 1999-09-28
US09/407,600 1999-09-28
PCT/US2000/026500 WO2001023375A2 (en) 1999-09-28 2000-09-26 Substituted pyridines and pyridazines with angiogenesis inhibiting activity

Publications (2)

Publication Number Publication Date
CA2385817A1 CA2385817A1 (en) 2001-04-05
CA2385817C true CA2385817C (en) 2010-05-04

Family

ID=23612752

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2385817A Expired - Lifetime CA2385817C (en) 1999-09-28 2000-09-26 Substituted pyridines and pyridazines with angiogenesis inhibiting activity

Country Status (35)

Country Link
EP (1) EP1228063B1 (enExample)
JP (1) JP4919567B2 (enExample)
KR (3) KR100895571B1 (enExample)
CN (3) CN100422172C (enExample)
AR (3) AR025752A1 (enExample)
AT (1) ATE422494T1 (enExample)
AU (1) AU782820B2 (enExample)
BG (1) BG65860B1 (enExample)
BR (1) BRPI0014382B8 (enExample)
CA (1) CA2385817C (enExample)
CO (1) CO5200835A1 (enExample)
CZ (1) CZ304767B6 (enExample)
DE (1) DE60041548D1 (enExample)
DO (1) DOP2000000070A (enExample)
EE (1) EE05258B1 (enExample)
ES (1) ES2320525T3 (enExample)
GT (1) GT200000158A (enExample)
HR (1) HRP20020308A2 (enExample)
HU (1) HU230223B1 (enExample)
IL (3) IL148880A0 (enExample)
MA (1) MA25563A1 (enExample)
MX (1) MXPA02003156A (enExample)
MY (3) MY143377A (enExample)
NO (1) NO20021520L (enExample)
NZ (1) NZ518589A (enExample)
PA (1) PA8503201A1 (enExample)
PE (1) PE20010607A1 (enExample)
PL (1) PL205957B1 (enExample)
RS (1) RS50369B (enExample)
RU (1) RU2260008C2 (enExample)
SK (1) SK287417B6 (enExample)
TW (1) TW593315B (enExample)
UA (1) UA75053C2 (enExample)
WO (1) WO2001023375A2 (enExample)
ZA (1) ZA200202760B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001279938B2 (en) * 2000-08-09 2007-01-25 Astrazeneca Ab Indole, azaindole and indazole derivatives having VEGF inhibiting activity
CN1308310C (zh) 2000-10-20 2007-04-04 卫材R&D管理有限公司 含氮芳环衍生物
JP2006503796A (ja) * 2001-12-21 2006-02-02 バイエル・フアーマシユーチカルズ・コーポレーシヨン ピリダジンまたはピリジン誘導体を含んでなる抗−脈管形成組み合わせ療法
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
MXPA05009687A (es) * 2003-03-11 2005-10-20 Novartis Ag Uso de derivados de isoquinolina para tratar cancer y enfermedades relacionadas con cinasa map.
WO2004089412A1 (ja) * 2003-04-08 2004-10-21 Mitsubishi Pharma Corporation 特異的nad(p)hオキシダーゼ抑制剤
JP4303726B2 (ja) 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
KR100553398B1 (ko) * 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-c]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
WO2006030941A1 (ja) 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. スルホンアミド含有化合物の血管新生阻害物質との併用
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
CA2579810C (en) 2004-09-17 2012-01-24 Eisai R&D Management Co., Ltd. Stable pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
US8304406B2 (en) 2006-04-15 2012-11-06 Bayer Intellectual Property Gmbh Compounds for treating pulmonary hypertension
US20090209580A1 (en) 2006-05-18 2009-08-20 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
AU2008211952B2 (en) 2007-01-29 2012-07-19 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
CN101481380B (zh) * 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
US20120077842A1 (en) 2009-08-19 2012-03-29 Eisai R&D Management Co., Ltd. Quinoline derivative-containing pharmaceutical composition
JP5898074B2 (ja) 2010-06-25 2016-04-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
EP2937337A4 (en) 2012-12-21 2016-06-22 Eisai R&D Man Co Ltd AMORPHIC FORM OF CHINOLINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
ES2687968T3 (es) 2013-05-14 2018-10-30 Eisai R&D Management Co., Ltd. Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
CN103396361B (zh) * 2013-07-24 2016-05-04 中国人民解放军第二军医大学 3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用
EP3187491A4 (en) 2014-08-28 2018-08-01 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
WO2016136745A1 (ja) 2015-02-25 2016-09-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
CN104804008B (zh) * 2015-03-27 2016-03-23 亿腾药业(泰州)有限公司 一种工业化生产甲磺酸特拉替尼的方法
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
EP3338779B1 (en) 2015-08-20 2021-06-30 Eisai R&D Management Co., Ltd. Lenvatinib in combination with etoposide and ifosfamide for use in treating a tumor
AU2018219637B2 (en) 2017-02-08 2023-07-13 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
CN107129502B (zh) * 2017-04-13 2022-08-05 泰州亿腾景昂药业股份有限公司 EOC315 Mod.I晶型化合物及其制备方法
CN110831597A (zh) 2017-05-16 2020-02-21 卫材R&D管理有限公司 肝细胞癌的治疗
WO2020219448A1 (en) * 2019-04-22 2020-10-29 Mirati Therapeutics, Inc. Naphthyridine derivatives as prc2 inhibitors
CN112830932B (zh) * 2020-12-25 2022-04-08 泰州亿腾景昂药业股份有限公司 特拉替尼的游离碱晶型及其制备方法与用途
IL312506A (en) 2021-11-08 2024-07-01 Progentos Therapeutics Inc Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1453897A (fr) * 1965-06-16 1966-07-22 Dérivés du thiophène et de thiéno pyridazines
GB1094044A (en) * 1965-07-12 1967-12-06 Vantorex Ltd Phthalazine derivatives
FR1516777A (fr) * 1966-08-02 1968-02-05 Innothera Lab Sa Dérivés du thiazole ainsi que de la thiazolo [4,5-d] pyridazine et leur préparation
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd 1―(3―ピリジルメチル)フタラジン誘導体
US5849741A (en) * 1994-08-09 1998-12-15 Eisai Co., Ltd. Fused pyridazine compounds
IL118631A (en) * 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
DE69942097D1 (de) * 1998-08-11 2010-04-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
EP1165085B1 (en) * 1999-03-30 2006-06-14 Novartis AG Phthalazine derivatives for treating inflammatory diseases
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
EP1254138B1 (en) * 2000-02-09 2005-05-11 Novartis AG Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase

Also Published As

Publication number Publication date
CN1769282A (zh) 2006-05-10
CN1420879A (zh) 2003-05-28
IL193367A (en) 2011-03-31
RU2260008C2 (ru) 2005-09-10
CZ304767B6 (cs) 2014-10-08
ES2320525T3 (es) 2009-05-25
IL148880A0 (en) 2002-09-12
CN100422173C (zh) 2008-10-01
AR082231A2 (es) 2012-11-21
HUP0202704A3 (en) 2003-12-29
HU230223B1 (en) 2015-10-28
HRP20020308B1 (enExample) 2013-01-31
MXPA02003156A (es) 2002-09-30
JP4919567B2 (ja) 2012-04-18
PL205957B1 (pl) 2010-06-30
KR100895571B1 (ko) 2009-04-29
SK5912002A3 (en) 2003-01-09
KR20080091505A (ko) 2008-10-13
IL193368A (en) 2011-05-31
MY143377A (en) 2011-05-13
NZ518589A (en) 2005-03-24
CN100374435C (zh) 2008-03-12
DE60041548D1 (de) 2009-03-26
PL366342A1 (en) 2005-01-24
BR0014382A (pt) 2003-06-24
EE05258B1 (et) 2010-02-15
HK1091818A1 (zh) 2007-01-26
AR025752A1 (es) 2002-12-11
ATE422494T1 (de) 2009-02-15
EP1228063A2 (en) 2002-08-07
IL193367A0 (en) 2009-02-11
CN100422172C (zh) 2008-10-01
NO20021520L (no) 2002-05-23
KR20080086547A (ko) 2008-09-25
IL193368A0 (en) 2009-02-11
SK287417B6 (sk) 2010-09-07
CZ20021444A3 (cs) 2002-08-14
BG106637A (bg) 2003-02-28
CA2385817A1 (en) 2001-04-05
JP2003526632A (ja) 2003-09-09
MY143580A (en) 2011-05-31
CO5200835A1 (es) 2002-09-27
AU782820B2 (en) 2005-09-01
KR100895572B1 (ko) 2009-04-29
PE20010607A1 (es) 2001-07-12
GT200000158A (es) 2002-03-16
ZA200202760B (en) 2003-10-29
YU22902A (sh) 2004-12-31
WO2001023375A2 (en) 2001-04-05
CN1769283A (zh) 2006-05-10
HRP20020308A2 (en) 2004-06-30
EE200200161A (et) 2003-08-15
DOP2000000070A (es) 2002-02-28
UA75053C2 (en) 2006-03-15
TW593315B (en) 2004-06-21
MA25563A1 (fr) 2002-10-01
NO20021520D0 (no) 2002-03-26
AU1569601A (en) 2001-04-30
WO2001023375A3 (en) 2002-05-02
MY135058A (en) 2008-01-31
KR20020038775A (ko) 2002-05-23
AR082232A2 (es) 2012-11-21
RS50369B (sr) 2009-11-10
BG65860B1 (bg) 2010-03-31
KR100890473B1 (ko) 2009-03-26
PA8503201A1 (es) 2002-08-26
HK1091819A1 (zh) 2007-01-26
BRPI0014382B8 (pt) 2021-05-25
BR0014382B1 (pt) 2014-04-01
HUP0202704A2 (hu) 2002-12-28
EP1228063B1 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
CA2385817C (en) Substituted pyridines and pyridazines with angiogenesis inhibiting activity
EP1208096B1 (en) Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity
US6689883B1 (en) Substituted pyridines and pyridazines with angiogenesis inhibiting activity
US20110263597A1 (en) Substituted pyridines and pyridazines with angiogenesis inhibiting activity
HK1091819B (en) Substitued pyridines and pyridazines with angiogenesis inhibiting activity
HK1091818B (en) Substitued pyridines and pyridazines with angiogenesis inhibiting activity

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20200928